Chromocell Therapeutics Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders’ Equity (Deficit)
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
**FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
| Preferred A Shares | Preferred A Shares Par | Preferred C Shares | Preferred C Shares Par | Common Shares | Par | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Deficit | |
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2022 | 600,000 | $60 | — | $— | $1,111,112 | $111 | $4,432,148 | $(6,138,856) | $(3,706,537) |
| Stock-based compensation | — | — | — | — | — | — | 272,221 | — | 272,221 |
| Net loss | — | — | — | — | — | — | — | (966,561) | (966,561) |
| Balance, March 31, 2023 | 600,000 | $60 | — | $— | $1,111,112 | $111 | $2,704,369 | $(7,105,417) | $(4,440,877) |
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
| Preferred A Shares | Preferred A Shares Par | Preferred C Shares | Preferred C Shares Par | Common Shares | Par | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Deficit | |
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2023 | 600,000 | $60 | — | $— | $3,906,300 | $391 | $7,074,646 | $(13,519,649) | $(6,444,552) |
| Stock-based compensation | — | — | — | — | — | — | 292,552 | — | 292,552 |
| Issuance cost from common stock issued for extension of bridge loan | — | — | — | — | 81,112 | 9 | 447,770 | — | 447,779 |
| Conversion of preferred stock | (600,000) | (60) | — | — | 499,429 | 50 | 10 | — | — |
| Common stock issued for cash | — | — | — | — | 1,100,000 | 110 | 5,971,890 | — | 5,972,000 |
| Standby agreement | — | — | — | — | 37,500 | 4 | (4) | — | — |
| Recission of common stock | — | — | — | — | (111,129 | (11) | (91,501) | — | (91,512) |
| Transfer of liabilities to Chromocell Corp. for preferred C shares | — | — | 2,600 | — | — | — | 2,153,362 | — | 2,153,363 |
| Common stock issued for conversion of notes | — | — | — | — | 253,492 | 25 | 1,362,796 | — | 1,362,821 |
| Net loss | — | — | — | — | — | — | — | (2,562,300) | (2,562,330) |
| Balance March 31, 2024 | — | $— | 2,600 | $1 | $5,766,704 | $578 | $17,211,521 | $(16,081,979) | $1,130,120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.